PGI45 Health-Related Quality of Life (HRQL) in Chronic Hepatitis C (CH-C) Patients Treated with Sofosbuvir Containing Interferon-Free Regimens  by Younossi, Z.M. et al.
A500  VA L U E  I N  H E A LT H  1 6  ( 2 0 1 3 )  A 3 2 3 – A 6 3 6  
PGI44
EconomIc and QualIty-of-lIfE BurdEn of modEratE to SEvErE 
IrrItaBlE BowEl SyndromE wIth conStIPatIon (IBS-c) In SPaIn: IntErIm 
analySIS of thE IBIS-c Study
Mearin F.1, Fortea J.2, Valveny N.3, Cortes X.2, Lindner L.2, Prior M.2
1Centro médico Teknon, Barcelona, Spain, 2Laboratorios Almirall S.A., Barcelona, Spain, 3TFS, 
Barcelona, Spain
Objectives: The IBIS-C study, currently ongoing, is the first to assess the burden 
of IBS-C in 6 European countries (France, Germany, Italy, Spain, Sweden, UK) . We 
present an interim analysis of the retrospective data from Spain. MethOds: This is 
an observational, retrospective-prospective (±6-months(m)) study in patients diag-
nosed in the last five years of IBS-C (Rome-III criteria) of moderate-to-severe degree 
(IBS-Symptom Severity Score(IBS-SSS)≥ 175). Quality-of-life(QoL) was assessed 
with the EuroQoL-5D(EQ-5D) and IBS-QoL. Results: We included 46 patients (62% 
severe, mean(±SD) 44.6±12.2 years, 83% women, time since diagnosis 2.8±3.6 years). 
According to IBS-SSS, 94% had abdominal pain in the last month (62% of time) and 
85% abdominal distention. Other prevalent symptoms were: constipation (96%), 
abdominal discomfort (72%) and bloating (59%). Mean IBS-QoL was 46±23, on a scale 
0-100 (worst QoL), and the most affected domains were “food avoidance” (mean:64) 
and “health worry” (60). Mean EQ-5D was 51±20, on a scale 0-100 (best QoL), and 93% 
and 70% of patients, respectively, reported problems in pain/discomfort and anxiety/
depression. In the previous 6m, 83% of patients consulted a primary care physi-
cian, and 89% a specialist (mostly a gastroenterologist)(mean(95%CI):2.8(1.4-4.3) 
and 2.0(0.9-3.1) visits, respectively). 20% of patients required emergency depart-
ment visits or hospitalization (mean stay:1.3(0.6-1.9) days). 76% of patients under-
went a diagnostic test (mean:2.1(1.3-2.9) tests). 89% of patients took medication 
(63% prescription drugs and 54% OTC medications), 26% received complementary 
therapies. The mean direct costs per patient for the National Health System(NHS) 
were € 1,025/6m(549-1627) and the mean costs for the patient were € 200/6m. 17% 
of patients had sick leave(mean:3.5 leaves; mean duration:58 days) and 46% had 
productivity losses(mean:49 hours). Mean indirect costs were € 991/6m. Total costs 
amounted to € 2216/6m. cOnclusiOns: Moderate-to-severe IBS-C has a great 
impact on health care resource utilization and productivity of patients, and the 
results suggest significant costs to the NHS and society. QoL can be severely affected.
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Objectives: Interferon-containing regimens for treatment of CH-C are associated 
with substantial side effects and significant impairment in HRQL. The aim of this 
study is to evaluate the effect of Interferon-free regimens on HRQL. MethOds: 
Three validated HRQL instruments, namely, Medical Outcomes Study-Short Form 
36 (SF-36), CLDQ-HCV (Chronic Liver Disease Questionnaire-HCV) and FACIT-F 
(Functional Assessment of Chronic Illness Therapy-Fatigue) were administered to 
previously untreated CH-C patients (N= 201) treated with interferon-free regimen 
(Sofosbuvir+Ribavirin) at baseline, during, and after treatment. Patients were ran-
domized to receive 16 weeks of active treatment or 12 weeks of active treatment 
followed by 4 weeks of blinded placebo. Historical data for interferon containing 
regimens were available for all these questionnaires. Results: Small decrements in 
most of the domains of all HRQL metrics were noted at weeks 4, 12, and 16 of active 
treatment regardless of the study arm (maximum observed decrements in HRQL 
summary scores between 3.3% and 8.8% compared to baseline, p< 0.05). There were 
no differences between the study arms at all time points (p> 0.05). These decrements 
were substantially better than historical data available for interferon-containing 
regimens (between 10.4% and 15.2% for the same scores, p< 0.0001). By week 4 of 
follow-up after treatment, some of the social and emotional well-being-related 
domains of FACIT-F improved significantly compared to their own baseline (by 4.9-
6.0%, p< 0.05). At the end of 12-week follow-up, all those domains as well as domains 
of CLDQ-HCV (activity, emotional, worry, systemic domains) further improved (by 
3.8-11.2%, p< 0.05), while physical and functional well-being-related domains of 
FACIT-F and SF-36 returned to their baseline levels or improved moderately (by 3.1-
8.3%, p< 0.05). cOnclusiOns: The impairment in HRQL in CH-C patients treated 
with an interferon-free regimen is minimal and diminishes soon after the end of 
treatment. This interferon-free regimen is associated with substantially better HRQL 
as compared to interferon-containing regimens.
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Objectives: Ulcerative colitis (UC) is a chronic inflammatory bowel disease. The 
objective of this systematic literature review (SLR) was to examine the evidence on 
the efficacy and safety of all available pharmacological interventions for moderate 
to severe UC. MethOds: A systematic literature search using a predefined strategy 
was performed in Medline®, EMBASE®, Medline-In-Process, Cochrane Library and 
BIOSIS from 1966 to 2013, to identify randomized controlled trials (RCTs) concern-
ing the efficacy and safety of available treatments in adult patients with moderate 
to severe UC. Studies reporting on mild-moderate UC patients were included if 
they reported results for the moderate subgroup separately. No language restric-
tions were applied to the search. Results: A total of 4344 abstracts were screened 
based on the predefined selection criteria, of which 4279 were excluded. In total, 
65 publications, reporting results from 65 RCTs were included (49 double blind), 
101 patients completed and returned the second package. Both scales had good 
overall fit to Rasch model (Chi2 p = 0.35; Chi2 p = 0.13 for activity limitations and 
QoL respectively) and unidimensionality of the scales was confirmed. No evidence 
of DIF by age or gender was found and the scales had good coverage of the meas-
urement constructs. Internal consistency was 0.91 for the QoL scale and 0.93 for 
Activity limitations. Good reproducibility was observed (QoL 0.91, Activity limita-
tions 0.89) and both scales were able to distinguish between self-perceived disease 
severity and general health status groups (p< .01). cOnclusiOns: The CLIQ is the 
first CD-specific PRO and is truly patient-based as its content was generated directly 
from CD patients. It is well accepted, completed by patients and is easy to score. 
Both scales measure a clear unidimensional construct and generate valid total 
scores. The scales have good consistency, reproducibility and promising construct 
validity. Studies are planned to assess responsiveness. The CLIQ will prove to be an 
important tool for assessing Activity limitations and QoL in clinical audit, practice 
and trials.
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Objectives: To identify symptoms significantly impacting health-related qual-
ity of life (HRQOL) and how changes in symptoms explain variability in HRQOL 
among adult patients with irritable bowel syndrome with constipation (IBS-
C). MethOds: IBS-C symptom and HRQOL data were pooled from two Phase 3 
trials (n= 1602) assessing efficacy and safety of linaclotide, a guanylate cyclase-C 
agonist approved for adult treatment of IBS-C in the US and moderate to severe 
IBS-C in Europe. IBS-C symptoms measured included abdominal (bloating, cramp-
ing, discomfort, fullness, pain) and bowel (spontaneous bowel movement [SBM] 
and complete SBM [CSBM] frequency, stool consistency, and straining) symptoms. 
HRQOL measures included: a disease-specific Irritable Bowel Syndrome-Quality 
of Life questionnaire (IBS-QOL), and generic HRQOL measures, the EuroQol-5D 
(EQ-5D) and Short Form-12 (SF-12). Analysis of variance evaluated relationships 
between Week 12 change from baseline in IBS-C symptoms and HRQOL, con-
trolling for demographics and baseline HRQOL. Results: Changes in IBS-QOL 
overall score were most significantly impacted by changes in abdominal fullness, 
cramping, and straining (beta coefficients: -1.1, -1.3, -1.7, respectively). The full 
model explained nearly half of the changes in IBS-QOL (R-Square: 0.42). Changes 
in EQ-5D were primarily driven by changes in abdominal bloating, cramping, and 
straining (beta coefficients: -0.009, -0.009, -0.011, respectively, R-Square: 0.49). 
Changes in SF-12 physical and mental component summaries (PCS and MCS) 
were best explained by changes in bloating, cramping, and straining (beta coef-
ficients: -0.41, -0.34, -0.53, respectively; R-square: 0.42), and abdominal fullness 
and CSBM frequency (beta coefficients: -0.59 and 0.26, respectively; R-square: 
0.35), respectively. cOnclusiOns: Improvements in abdominal cramping and 
straining at Week 12 compared to baseline were associated with improvements 
in HRQOL as measured by the IBS-QOL, EQ-5D and SF-12 PCS. Improvements in 
abdominal bloating and fullness, and increases in CSBMs were also associated 
with HRQOL improvements. Targeting improvement in specific IBS-C symptoms 
may result in increased patient HRQOL.
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Objectives: Liver diseases (LDs) have a high impact on morbidity, mortality and 
health-related quality of life (HRQoL). LDs may have different impact on patients’ 
HRQoL. The aim of our study was to evaluate HRQoL in the major liver conditions: 
hepatitis B(HBV), hepatitis C(HCV), cirrhosis(compensated and decompensated), 
hepatocellular carcinoma(HCC), autoimmune hepatitis(AIH), primary biliary 
cirrhosis(PBC), primary sclerosing cholangitis(PSC), NAFLD/NASH, patients in the 
liver transplant list and post-transplant. MethOds: A naturalistic, prospective, 
multicenter study has been conducted to generate and validate a set of health care 
outcomes indicators for the major liver conditions. LDs patients (age> 18 years) were 
enrolled in 3 major Italian medical centers and are still being followed up (median 
f-up:13 months). Within this study, socio-demographic, clinical and HRQoL were 
collected using the EQ-5D-3L. The HRQoL data was analyzed dividing the patients 
in sub-groups according to the most recently diagnosed and most severe condi-
tion. Results: We enrolled 3,217 patients, 64.8% male, aged 19-91 (median= 61) 
years; 95.0% of them filled in the EQ-5D at baseline visit. Patients in the HCC group 
were 22.6%; while in the AIH group were 1.6%. The highest percentage of problems 
in Mobility dimension (39.2%) was reported by decompensated cirrhosis sub-group, 
the highest percentage in Self-care (22.6%) and Usual Activities (47.1%) by patients 
in liver transplant list, in Pain/Discomfort (59.2%) by AIH and in Anxiety/Depression 
(57.8%) by PBC. The HBV sub-group reported the best HRQoL with a mean EQ-5D 
VAS of 77.8; while AIH and listed for liver transplant patients reported the worst 
HRQoL levels (mean EQ-5D VAS= 67.7 and 63.5, respectively). cOnclusiOns: our 
study shows how HRQoL is different between LDs and how it is negatively related 
with the clinical severity. Understanding the different impact of LDs on the patients’ 
HRQoL could help physicians and decision makers to better estimate the burden of 
these conditions and to improve the quality of care.
